Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01517451 · ClinicalTrials.gov registry record · Phase 1
Radiation and Androgen Ablation for Prostate Cancer
A Phase 1 study of Adenocarcinoma of the Prostate, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 3
- Study locations
NCT01517451: Completed Phase 1 study of Adenocarcinoma of the Prostate, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
NCT01517451 is a Phase 1 study of Adenocarcinoma of the Prostate that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 45 participants, below the 107-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (58% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01517451, a Phase 1 study of Adenocarcinoma of the Prostate, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 3
- Study locations
Study Summary
A study to see how effective and tolerable radiation therapy along with androgen deprivation therapy is in treating prostate cancer.
Primary Outcome
To assess 5-year biochemical failure free rate (BFFR) associated with image-guided radiation therapy in doses of 7.25 Gy every other day to a total dose of 36.25 Gy (5 fractions) along with 4 months of androgen deprivation therapy (ADT) neoadjuvantly and concurrently. BFFR is defined as binary indicator whether PSA has increased by 2 ng/ml or more above the nadir PSA any time before the end of 5 years as the number of events.
Conditions Studied
Interventions
- RADIATION Radiation Therapy
- DRUG Androgen Deprivation Therapy (ADT)
Study Locations (3)
Maryland
- The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins - Baltimore
- Suburban Hospital - Bethesda
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2013-05-22 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 1 |
What the finished NCT01517451 record still lists
NCT01517451 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 107-participant average among 21 other Adenocarcinoma of the Prostate trials with a reported enrollment target (58% lower).
The record links to 1 condition, with Adenocarcinoma of the Prostate appearing as the primary indexed condition, and to 2 interventions - of which Radiation Therapy is the first listed.
NCT01517451 reports a single indexed study location in Maryland, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT01517451 about?
NCT01517451 is a clinical study titled "Radiation and Androgen Ablation for Prostate Cancer". A study to see how effective and tolerable radiation therapy along with androgen deprivation therapy is in treating prostate cancer.
What is the current status of trial NCT01517451?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2013-05-22. Estimated completion is 2025-12-31.
What conditions does trial NCT01517451 study?
This clinical trial studies the following conditions: Adenocarcinoma of the Prostate.
What interventions are being tested in trial NCT01517451?
The interventions under investigation include: Radiation Therapy (RADIATION), Androgen Deprivation Therapy (ADT) (DRUG).
Who is sponsoring clinical trial NCT01517451?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01517451 being conducted?
This trial has 3 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenocarcinoma of the Prostate
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01517451's enrollment target sits among peer trials
45 10th of 21 higher than 11 of 21 other Adenocarcinoma of the Prostate trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Adenocarcinoma of the Prostate trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
ACTIVE NOT RECRUITING · Phase 1
-
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer
COMPLETED · Phase 1
-
Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
COMPLETED · Phase 1
-
Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI